Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX

TG THERAPEUTICS

TG THERAPEUTICS, INC.

TG THERAPEUTICS trial registry — 54 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
Status
Public
HQ
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
Founded
2011
Employees
521
Programs
39
Drugs
23
Patents
7
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

TG THERAPEUTICS clinical trials

Registry index of 54 ClinicalTrials.gov studies linked to TG THERAPEUTICS programs — each row shows trial ID, program name, phase, status, and indication.

TG THERAPEUTICS trial registry — 54 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for TG THERAPEUTICS.

  1. TG1101-RMS-SC101 — Phase 1

    Clinical update

  2. TG1101-RMS401 — Phase 3

    Clinical update

  3. TG1101-RMS-PED304 — Phase 3

    Clinical update

  4. ublituximab — Phase 3

    Clinical update

  5. Ublituximab, ublituximab — Phase 3

    Clinical update

  6. Ublituximab — Phase 2

    Clinical update

  7. Ublituximab — Phase 3

    Clinical update

  8. Ublituximab — Phase 3

    Clinical update

Trial registry

54 studies

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.